Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics

This article was originally published in PharmAsia News

Executive Summary

WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year
Advertisement

Related Content

From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
PhamAsia News Top Editors' Picks Of 2010
PhamAsia News Top Editors' Picks Of 2010
Chinese CRO ShangPharma Moves Into Biologics To Follow Customer Trend
China's Pro-science Leaders To Make Biotech Drugs A Central Plank In New Five Year Plan
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit
WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings
Advertisement
UsernamePublicRestriction

Register

SC073568

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel